9KE9 | pdb_00009ke9

Crystal structure of the PIN1 and fragment 22 complex.


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.25 Å
  • R-Value Free: 
    0.239 (Depositor), 0.242 (DCC) 
  • R-Value Work: 
    0.211 (Depositor), 0.213 (DCC) 
  • R-Value Observed: 
    0.213 (Depositor) 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.0 of the entry. See complete history


Literature

Uncovering druggable hotspots on Pin1 via X-ray crystallographic fragment screening.

Xiao, Q.Tang, J.Shu, H.Wu, T.Zhang, H.Wang, W.Wang, L.Qin, W.

(2025) Eur J Med Chem 299: 118048-118048

  • DOI: https://doi.org/10.1016/j.ejmech.2025.118048
  • Primary Citation of Related Structures:  
    9JYO, 9JYP, 9JYR, 9JYT, 9JYV, 9JZ2, 9JZ3, 9JZ4, 9JZ6, 9JZG, 9JZS, 9JZU, 9JZV, 9KE7, 9KE9, 9KEB, 9KEC, 9KEL, 9KEQ, 9KES, 9KEW, 9KEY, 9KEZ, 9KF0, 9KFC, 9KFH, 9KG9, 9KXH, 9KXI, 9KXJ, 9KXL, 9KXM, 9KXN, 9KXQ, 9V92

  • PubMed Abstract: 

    Pin1 is a phosphorylation-dependent peptidyl-prolyl isomerase that specifically recognizes and catalyzes the cis-trans isomerization of pSer/Thr-Pro motifs. It plays a pivotal role in cell cycle regulation, signal transduction, and tumorigenesis. Due to its overexpression in many cancer types, Pin1 has emerged as a promising target for the development of anticancer drugs. However, the relatively shallow and flat surface of Pin1 presents significant challenges for traditional small-molecule inhibitor design. To overcome these limitations, we employed an X-ray crystallography-based fragment screening strategy and identified approximately 50 Pin1-fragment complex structures from a curated fragment library. Systematic structural analysis revealed several druggable binding hotspots, including the well-characterized catalytic center (Site 1) and a neighboring region near the catalytic residue Cys113 (Site 2). Both sites supported stable binding with diverse fragment scaffolds. Notably, several fragments displayed cooperative binding across multiple sites, highlighting their potential as scaffolds for multifunctional inhibitor design. Additionally, a subset of fragments showed reactivity toward Cys113, and their covalent binding modes were confirmed through crystallographic and mass spectrometric analyses. Enzymatic inhibition assays further demonstrated that several fragments effectively suppressed Pin1 activity in solution, validating their potential as lead compounds. In summary, this study systematically mapped functional binding pockets on Pin1 through a structure-driven fragment screening approach, expanded its druggable landscape, and identified key structural features and fragment chemotypes to guide the development of selective, well-defined Pin1 inhibitors.


  • Organizational Affiliation
    • National Facility for Protein Science in Shanghai, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, 201210, People's Republic of China.

Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1163Homo sapiensMutation(s): 0 
Gene Names: PIN1
EC: 5.2.1.8
UniProt & NIH Common Fund Data Resources
Find proteins for Q13526 (Homo sapiens)
Explore Q13526 
Go to UniProtKB:  Q13526
PHAROS:  Q13526
GTEx:  ENSG00000127445 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ13526
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.25 Å
  • R-Value Free:  0.239 (Depositor), 0.242 (DCC) 
  • R-Value Work:  0.211 (Depositor), 0.213 (DCC) 
  • R-Value Observed: 0.213 (Depositor) 
Space Group: P 31 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 70.266α = 90
b = 70.266β = 90
c = 79.641γ = 120
Software Package:
Software NamePurpose
PHENIXrefinement
HKL-3000data scaling
HKL-3000data reduction
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Not funded--

Revision History  (Full details and data files)

  • Version 1.0: 2025-08-27
    Type: Initial release